Share Twitter LinkedIn Facebook Email Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) "“ measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC. https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/
Targeting SCD1 in KRAS Mutant Non-Small Cell Lung Cancer: A Novel Therapeutic Strategy Non-Small Cell Lung Cancer 3 Mins Read
What is the new treatment for non-small cell lung cancer? Changes in the Perioperative Setting [54 Slides] Karen Reckamp, MD Non-Small Cell Lung Cancer 4 Mins Read
FDA Approves Amivantamab with Chemo for First-Line NSCLC with EGFR Exon 20 Insertion Mutations [EXCLUSIVE VIDEO] Non-Small Cell Lung Cancer 3 Mins Read